Shamrock Asset Management Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Shamrock Asset Management reduced its stake in Johnson & Johnson by 48.7% during the most recent quarter end. The investment management company now holds a total of 7,479 shares of Johnson & Johnson which is valued at $843,182 after selling 7,101 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on May 2, 2016.Johnson & Johnson makes up approximately 0.50% of Shamrock Asset Management’s portfolio.

Johnson & Johnson closed down -0.14 points or -0.12% at $112.74 with 60,99,860 shares getting traded on Friday. Post opening the session at $112.58, the shares hit an intraday low of $112.275 and an intraday high of $113.05 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Gamble Jones Investment Counsel reduced its stake in JNJ by selling 3,412 shares or 1.32% in the most recent quarter. The Hedge Fund company now holds 254,162 shares of JNJ which is valued at $28,654,224. Johnson & Johnson makes up approx 3.19% of Gamble Jones Investment Counsel’s portfolio.Nordea Investment Management Ab boosted its stake in JNJ in the latest quarter, The investment management firm added 1,346,235 additional shares and now holds a total of 12,075,174 shares of Johnson & Johnson which is valued at $1,353,385,502. Johnson & Johnson makes up approx 4.06% of Nordea Investment Management Ab’s portfolio.Bank Of Stockton boosted its stake in JNJ in the latest quarter, The investment management firm added 1,000 additional shares and now holds a total of 12,243 shares of Johnson & Johnson which is valued at $1,372,195. Johnson & Johnson makes up approx 0.75% of Bank Of Stockton’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.